IGF-I serum levels have been demonstrated as being associated with prostate cancer (PCa) and can serve as a predictive factor for the risk of PCa development. However, the role of IGF-II in PCa and its importance as a predictive marker is still unclear. Our aim was to determine PSA and IGF-II serum levels in patients with PCa and benign prostatic hyperplasia (BPH) and to analyse the value of IGF-II as an additional predictive factor in the diagnostics of PCa.
112 patients who underwent surgery for BPH or PCa (no hormonal treatment, no further malignancies) were included in this study ((I) 38 PCa, PSA
PSA levels were (I) 5.7
This study provides evidence that IGF-II serum levels may serve as an additional parameter for (a) improved determination of tumor staging and (b) better discrimination between BPH and PCa.
Keywords: Biological markers, Insulin-like Growth factor II, Prostate-specific antigen, Prostatic neoplasms, Prostatic hyperplasia.
a Department of Urology, University Hospital Mannheim, Heidelberg University, Germany
b Department of Medical Biometrics and Statistics, University Hospital Mannheim, Heidelberg University, Germany
c Research Group “Hormones and Signal Transduction”, Deutsches Krebsforschungszentrum, Heidelberg, Germany
d Department of Pathology, University Hospital Mannheim, Heidelberg University, Germany
© 2005 Elsevier B.V., All rights reserved.